The Biotech Recovery Gathers Speed in Q2

The Biotech Recovery Gathers Speed in Q2

Endpoints’ latest analysis, powered by DealForma data, shows that biopharma dealmaking continued its strong recovery in Q2 2026, with accelerating M&A, IPO, and partnership activity despite ongoing competitive and regulatory challenges. Read it here

DealForma Research

Explore More
AI / Machine Learning R&D, M&A, Ventures & IPOs - H1 2026 Review

AI / Machine Learning R&D, M&A, Ventures & IPOs – H1 2026 Review

MedTech, Device, Digital Health and Wearables M&A - H1 2026 Review

MedTech, Device, Digital Health and Wearables M&A – H1 2026 Review

Biopharma Therapeutics and Platforms IPO Activity, Follow-ons and PIPEs – Q2 2026 Review

Biopharma Therapeutics and Platforms IPO Activity, Follow-ons and PIPEs – Q2 2026 Review

All of this by stage, disease indication, modality, target…

Schedule your Demo
+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures
DealForma Logo

DealForma is the biopharma deal database providing you comprehensive information and dedicated analyst support to help you be more confident using quality data in your business development research.

Linkedin

Database

Company

Comparisons

Website Design by Once Interactive